• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

Giuseppe

Emeritus
Toxic vaccine threat to babies - Science, News - The Independent

Toxic vaccine threat to babies

By Steve Connor, Science Editor
Wednesday, 25 February 2009

Thousands of babies may have been injected with a vaccine contaminated with a potentially lethal blood-poisoning bacterium, it emerged last night.


Health officials withdrew 21,000 doses of the meningitis C vaccine from GP clinics around the country that were sent out about a week ago. It is not known how many babies may have received the jab in that time. More than 60,000 doses of the vaccine, which is offered to all four-month-old babies, could be contaminated with the hospital-acquired infection ? the Staphylococcus aureus bacterium ? but a third of these had already been sent to vaccination clinics before officials became aware of the problem.

Officials within the Department of Health and the vaccine's manufacturers are believed to have known of the problem for several days but only issued an emergency recall of the vaccine last night after being contacted with details of the potential contamination by The Independent.

Last night the Tory health team demanded answers about why it had taken so long to withdraw the vaccine and said there may need to be an inquiry.

It is possible that many hundreds or even thousands of children could have received at least one dose. One official said that there have as yet been no reports of any adverse reactions to the meningitis C injection.

The revelation comes at a critical time given that many parents are still suspicious about childhood vaccinations, largely as a result of the unfounded scare over the measles, mumps and rubella (MMR) vaccine which was incorrectly linked to childhood autism in a study published more than 10 years ago that has now been retracted.

The meningitis C vaccine, sold under the trade name Menjugate, is manufactured and packed in Italy by Novartis, a multinational pharmaceutical company. One insider told The Independent that any contamination with Staphylococcus ? which is related to MRSA ? would have occurred during the preparation of the vaccine in the manufacturing centre in Siena.

The company confirmed last night that two lots of the vaccine ? some 61,117 doses imported into Britain ? could be contaminated and that 21,301 doses have been sent to GP surgeries over the past week for the Government's childhood vaccination programme.

The Medicines and Healthcare products Regulatory Agency (MHRA) was working last night with Novartis to recall all the remaining doses of vaccine that had been sent to GPs but which had not yet been used. A spokeswoman for Novartis said that the company's press office was made aware of the problem on Monday but she could not say when the company had informed the Department of Health.

"Novartis is working with the relevant government authorities including the MHRA and the Italian Ministry of Health to recall two lots of Menjugate distributed in the UK," the spokeswoman said.

"We are investigating a sterility testing positive result from samples of one lot of aluminium hydroxide solvent which was used in the packaging of two lots of Menjugate. The solvent lot passed all release specifications. The subject result was identified during a special study," she said.

The MHRA said in a statement issued last night that it was first alerted to the problem on Tuesday. "The tested samples were of one batch of solvent used in two batches of Menjugate Kit, and were identified positive for the bacteria Staphylococcus aureus during the sterility test. They [the two samples] were not distributed to the UK market," it said.

"However, as a precaution, these two batches of Menjugate Kit which were distributed in the UK are being recalled. There is at present no evidence that these two batches of Menjugate Kit are affected," it added.

A spokeswoman for the MHRA said that, despite the recall, there was no evidence of any risk to children from the vaccine but she could not say how many babies could have already been injected with the vaccine. "The recall is purely a precautionary measure. There is no reason for UK children to be at any risk from this product. All vaccine supplied to the UK had passed the tests required for its use," she said.

Andrew Lansley, the shadow Health Secretary, said: "This is very disturbing news. We will be looking to the Government to give the fullest possible account of what's happened."

Parents who bring their children for immunisation need to have the greatest possible confidence that the vaccines concerned are safe and their children won't come to harm.

"I will be looking to the Government to provide this specific assurance."

Mike Penning, a Tory health spokesman, said: "Parents take vaccines to make their children safe, not put them at risk. They will want answers as to why it took so long to withdraw the vaccine. The Government has got to come clean about its decision-making and when the Secretary of State was told what happened. We could need an independent inquiry to establish the facts."

The Menjugate vaccine ? one of two distributed in the UK ? was the subject of safety concerns in 2000 soon after it was introduced into Britain. However, the Medicines Control Agency said at the time that the fears were unfounded.

Pat Troop, then deputy chief medical officer, said in 2000 the meningitis C vaccine was very safe. The number of adverse reactions ? such as headaches, and sore arms ? were normal for this sort of vaccine, she said.
-
<cite cite="http://www.independent.co.uk/news/science/toxic-vaccine-threat-to-babies-1632069.html">Toxic vaccine threat to babies - Science, News - The Independent</cite>
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (2/25/2009)

Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (2/25/2009)

Class 2 Drug Alert (action within 48 hours): Novartis Vaccines and Diagnostics S.r.l. - Menjugate Kit - Meningococcal group C conjugate vaccine - EL (09)/A06

DRUG ALERT
Class 2 medicines recall
Action within 48 hours
Pharmacy or equivalent level recall
25 February 2009 - EL (09)/A06 - Our ref: MDR 44-02/09

Dear Healthcare Professional,

Novartis Vaccines and Diagnostics S.r.l.

Menjugate Kit

Meningococcal group C conjugate vaccine
PL 13767/0023-13767/0024

Batch Number / Expiry Date / Pack Size / First Distributed
235012A / July 2011 / Single Dose / 22 January 2009
236011 / July 2011 / Single Dose / 20 February 2009


Novartis Vaccines and Diagnostics S.r.l. are recalling the above batches of Menjugate Kit as a precaution following an initial failure of a sterility test carried out as part of a shipping validation study of the batch of aluminium hydroxide solvent used in them, batch number 088902. This batch passed its sterility test at the time of release.

Recipients are asked to quarantine any stock and notify Movianto UK Ltd on 01234 248789 that you have product to be collected. Alternatively please email Rosina.Clark@movianto.com with details of the product to be collected.

In the UK, Novartis Vaccines? co-promotion partner is Sanofi Pasteur MSD Ltd. However for information regarding this action please contact Novartis Vaccines and Diagnostics Limited on 08457 451500.

Primary Care Trusts are asked to bring this information to the attention of relevant clinics, General Practitioners and Community Pharmacists by copy of this letter.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor, DMRC

Questions and answers

Q Why are these lots of Menjugate Kit being recalled?
A The tested samples were of one batch of solvent used in two batches (235012A and 236011) of Menjugate Kit, and were identified positive for the bacteria Staphylococcus aureus during the sterility test, they were not distributed to the UK market. However, as a precaution, these two batches of Menjugate Kit which were distributed in the UK are being recalled. There is at present no evidence that these two batches of Menjugate Kit are affected.

The batches concerned were tested prior to release and complied with all tests, including the sterility test. Product supplied to the UK was shipped using routine validated transport. The tested samples that failed the sterility test were part of a non-routine study undertaken by the company and were not part of the UK market product.

Q If there are no problems why have these batches of vaccine been withdrawn?
A This is an entirely precautionary action. There is no reason to believe the UK batches are at risk of the problems of the material that was tested. These batches of vaccine have been withdrawn to ensure that there are no grounds for anyone to be concerned. The MHRA have no reports of adverse reactions associated with these batches.

Q. Are UK children at risk?
A. There is no reason for UK children to be at any risk from this product. All vaccine supplied to the UK had passed the tests required for its use.

Q. What action should be taken if a child has recently had a MenC vaccine?
A. Other meningitis vaccines, and other batches of Menjugate, are not affected by this recall. If a parent has any concerns about the MenC vaccine administered to their child they should discuss this with their doctor.

Q Are there any manufacturing issues with this Solvent
A Novartis are investigating the root cause for the non-conforming sterility result. We have no evidence that any other lots of Aluminum-hydroxide solvent would be impacted.

MHRA Distribution (further recipients by cascade):

Regional Contacts for NHS Trusts and Provider Units
Chief Pharmacists: England, Scotland, Wales, Northern Ireland
Prison Health Policy Unit (DH)
Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar
Special Hospitals
Healthcare Commission for distribution to Independent Health Care Establishments
Primary Care Trusts (England)
-
http://www.mhra.gov.uk/Publications/Safetywarnings/Drugalerts/CON038882
-----
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

United Kingdom. Baby vaccine withdrawn over contamination fears - Telegraph

Baby vaccine withdrawn over contamination fears

Thousands of doses of a meningitis C vaccine for babies have been withdrawn over fears that they have been contaminated with blood-poisoning bacteria.


By Murray Wardrop
Last Updated: 7:26AM GMT
26 Feb 2009

More than 20,000 vials of the vaccine distributed to GP surgeries across the country have been recalled after samples tested positive for the bacteria Staphylococcus aureus.

It is thought that a further 40,000 doses could be contaminated with the hospital-acquired infection, but had not yet been sent to vaccination clinics when officials were alerted to the problem.

The Medicines and Healthcare products Regulatory Agency (MHRA) last night said that no children are believed to be at risk and emphasised that the doses had been recalled purely as a precautionary measure.

The vaccination, produced by Swiss pharmaceutical company Novartis, is offered to all four-month-old babies and has only been available in Britain since January.

Andrew Lansley, the shadow Health Secretary, last night described the incident as ?very disturbing? and demanded an explanation from the government.

Novartis Vaccines and Diagnostics said it had been alerted to a sterility issue in the solvent for its Menjugate Kit, which is distributed to Britain from Italy.

The company confirmed last night that 61,117 doses of the vaccine could be contaminated.It said that 21,301 of the doses have been sent to GP surgeries acros Britain over the past week for the Government?s childhood vaccination programme.

An MHRA spokeswoman said that some samples had tested positive for the bacteria, but these had not been brought over to Britain.

However, it was forced to recall the two batches which have been distributed for further tests to be carried out and comparisons to be drawn.

It is not known how many, if any, children have received the vaccine but there have not been any reports of adverse reactions.

The spokeswoman said: ?The tested samples that failed the sterility test were part of a non-routine study undertaken by the company and were not part of the UK market product.

?Further investigations into the cause of the failure are under way by the company.

?There is currently no evidence to show that there is any risk to children.?

A spokeswoman for Novartis said: ?Novartis is working with the relevant government authorities including the Medicines and Healthcare Products Regulatory Agency and the Italian Ministry of Health to recall two lots of Menjugate Kit distributed in the UK.

?We are investigating a sterility testing positive result from samples of one lot of Aluminum hydroxide solvent which was used for the packaging of two lots of Menjugate.

?The solvent lot passed all release specifications; the subject result was identified during a special study.?

The news comes amid scepticism from parents about childhood vaccinations following the unfounded scare over the measles, mumps and rubella (MMR) vaccine which was incorrectly linked to autism.

Mr Lansley said: ?This is very disturbing news. We will be looking to the Government to give the fullest possible account of what?s happened.

?Parents who bring their children for immunisation need to have the greatest possible confidence that the vaccines concerned are safe and their children won?t come to harm. I will be looking to the Government to provide this specific assurance.?

Mike Penning, a Conservative health spokesman, said: ?Parents take vaccines to make their children safe, not put them at risk.

?They will want answers as to why it took so long to withdraw the vaccine. The Government has got to come clean about its decision-making and when the Secretary of State was told what happened. We could need an independent inquiry to establish the facts.?

A Department of Health spokeswoman said last night: ?We are aware that the Medicines and Healthcare Products Regulatory Agency has recalled two batches of meningitis C vaccine. This is as a precautionary measure and we are not aware of any problems in the UK.

?All batches of the vaccine that have come into the UK have passed all their tests including sterility.

?If people have had this vaccine recently and are concerned contact your GP or NHS Direct.?
-
<cite cite="http://www.telegraph.co.uk/health/healthnews/4809324/Baby-vaccine-withdrawn-over-contamination-fears.html">Baby vaccine withdrawn over contamination fears - Telegraph</cite>
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

United Kingdom. Meningitis C vaccine recalled over contamination fears - guardian.co.uk

Contamination fears prompt meningitis C vaccine recall

? Sterility issue in solvent for Italian medicine
? Watchdog says no children believed to be at risk

* Press Association
* guardian.co.uk, Thursday 26 February 2009 09.11 GMT

A drugs company has recalled batches of a meningitis C vaccine due to contamination fears.


Novartis Vaccines and Diagnostics said it had been alerted to a sterility issue in the solvent for its Menjugate Kit, which is from Italy and distributed in the UK.

The Medicines and Healthcare Products Regulatory Agency (MHRA) said no children were believed to be at risk from the solvent and emphasised it had been recalled purely as a precautionary measure.

A spokeswoman said some samples had tested positive for the bacteria Staphylococcus aureus, but these had not been brought over to the UK.

However, the two batches which had been distributed had to be recalled for further tests to be carried out and comparisons to be drawn.

"The tested samples that failed the sterility test were part of a non-routine study undertaken by the company and were not part of the UK market product," the spokeswoman said.

Around 20,000 vials are believed to have been distributed to doctors' surgeries around the country, but it is not known how they have been spread out.

The vaccination has only been available in the UK since January.

The MHRA spokeswoman said:
"Further investigations into the cause of the failure are under way by the company.
"There is currently no evidence to show that there is any risk to children."

A spokeswoman for Novartis said:
"Novartis is working with the relevant government authorities including the Medicines and Healthcare Products Regulatory Agency and the Italian ministry of health to recall two lots of Menjugate Kit distributed in the UK.
"We are investigating a sterility testing positive result from samples of one lot of Aluminum hydroxide solvent which was used for the packaging of two lots of Menjugate.
"The solvent lot passed all release specifications; the subject result was identified during a special study."

She said the company was "committed to being a safe and reliable provider of vaccines".

A Department of Health spokeswoman said it was not aware of any problems with the vaccine in the UK and described the recall as a precautionary measure.

"All batches of the vaccine that have come into the UK have passed all their tests, including sterility.
"If people have had this vaccine recently and are concerned, contact your GP or NHS Direct."

The shadow health secretary, Andrew Lansley, said the department should act urgently to reassure parents about the safety of the vaccine.
"When parents take their children for vaccinations it is essential that they are confident that the vaccine is safe. I hope that ministers will provide that reassurance as quickly as possible."
-
<cite cite="http://www.guardian.co.uk/lifeandstyle/2009/feb/26/meningitis-c-vaccine-recall">Meningitis C vaccine recalled over contamination fears | Life and style | guardian.co.uk</cite>
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

Meningitis C vaccine: contaminated batches never entered UK | Society | guardian.co.uk

Contaminated meningitis C vaccine 'never entered UK'

Government watchdog reassures public that meningitis C vaccine is safe after batches were recalled from use


* David Batty
* guardian.co.uk, Thursday 26 February 2009 18.01 GMT

The only samples of a meningitis C vaccine recalled over contamination fears to test positive for bacteria were part of a safety study and never entered the UK, the government's drug safety watchdog said today.


After batches of the vaccine were recalled earlier today, the Medicines and Healthcare Products Regulatory Agency (MHRA) said that the only samples to have tested positive for the bacteria Staphylococcus aureus were part of a study by the vaccine's manufacturer to see whether doses could be safely transported via air.

Novartis Vaccines and Diagnostics flew samples from two batches destined for the UK from its factory in Italy to a third country, where they were tested to check whether changes in air pressure had affected the vaccine vials.

The tests revealed traces of Staphylococcus aureus in the aluminium hydroxide solvent in which the vaccine is suspended.

An MHRA spokeswoman said:
"Novartis flew samples from the two batches bound for the UK to a third country to test whether the vials would remain secure under the varying air pressure.
"They needed to test the seals on the vaccine vials because seals expand and contract with changes in air pressure.
"These samples tested positive for Staphylococcus aureus bacteria. They were quarantined by Novartis and did not enter into any supply chain."

The two batches from which the study samples were taken were transported via road and sea to the UK, following standard practice, she added.

There have been no reports of adverse reactions to vaccines from these batches in the UK, but Novartis has recalled them for testing as a precautionary measure.

Kent Woods, the MHRA chief executive, says:
"Parents should not be concerned over this recall, as there is currently no evidence to show that UK children have been put at risk."

Doctors' leaders today reassured the public that there was no need for another vaccine scare over the matter.

Steve Field, chairman of the Royal College of GPs, said:
"The last thing we want is another scare over a highly successful vaccine. This is a case of the vaccine manufacturer being incredibly careful.
"I'm sure if there was any problem with the batches sent to the UK that doctors and nurses would have noticed adverse reactions by now."

Around 17,000 vials of the Novartis Menjugate Kit have been distributed to doctors' surgeries around the UK.

A Department of Health spokesman said it was not aware of any problems with the vaccine in the UK and described the recall as a precautionary measure.

"All batches of the vaccine that have come into the UK have passed all their tests, including sterility.
"If people have had this vaccine recently and are concerned, contact your GP or NHS Direct."
-
<cite cite="http://www.guardian.co.uk/society/2009/feb/26/children-health">Meningitis C vaccine: contaminated batches never entered UK | Society | guardian.co.uk</cite>
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

Press release: No evidence of any risk to UK children over meningitis vaccine : MHRA

Press release: No evidence of any risk to UK children over meningitis vaccine

Press release
Date: 26 Feb 2009
Time: 16:00
Subject: Recall of Menjugate Kit vaccine
Contact: Press Office 020 7084 3535/3564 or press.office@mhra.gsi.gov.uk
Out-of-hours 07770 446 189

The Medicines and Healthcare products Regulatory Agency (MHRA) yesterday issued a precautionary drug alert for two batches of Menjugate Kit (a meningitis vaccine made by Novartis) from GP surgeries, with a total of 17,000 doses.


There is currently no evidence of any risk to UK children, and there have been no reports of any infections following vaccination.


The two batches sent to the UK passed all the normal tests, including a sterility test, to ensure the safety, quality and effectiveness of the product before leaving the manufacturing site in Italy and travelling by road to the UK.

Individual GP practices that received vaccine from these batches have been contacted by the Department of Health to recall them.

Professor Kent Woods, MHRA Chief Executive, says:
?Parents should not be concerned over this recall, as there is currently no evidence to show that UK children have been put at risk. Novartis are recalling these two batches as a precautionary measure.
However, if parents are in any way concerned, then they can contact their doctor about the issue or contact NHS Direct.?

Novartis sent samples from the same batches overseas to test whether the sample would remain secure under the varying air pressure. The samples, which passed sterility tests before transportation, were re-tested when they reached their destination. These samples tested positive for Staphylococcus aureus bacteria. They were quarantined by Novartis and did not enter into any supply chain.

The batches sent to the UK were transported by road (their normal transportation method) and have not been exposed to the air pressure testing.

Further investigations into the cause of the test results from the samples sent to the US are underway by the company. Tests have also begun on batches in the UK.

The MHRA was first alerted by Novartis on 24 February 2009 that there was a sterility issue with the solvent in the Menjugate Kit from the US samples. The solvent is used to mix the meningitis vaccine.

Notes to Editor
1. What action should be taken if a child has recently had a MenC vaccine? Other meningitis vaccines, and other batches of Menjugate, are not affected by this recall.
2. Product name ?Menjugate Kit?; batch numbers 236011 and 235012A3. The figure has is now 17,000 doses rather than the 21000 doses used yesterday. 17000 doses from these batches of vaccine have been distributed to GPs. We found out today that the 21000 figure included stock that had been distributed and stock that was waiting to be sent out.
4. A copy of the drug alert can be found at our website: http://www.mhra.gov.uk/Publications/Safetywarnings/Drugalerts/CON038882
-
<cite cite="http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON038896">Press release: No evidence of any risk to UK children over meningitis vaccine : MHRA</cite>
 
Re: United Kingdom. Vaccine Recall, Men-C suspected to be tainted with bacteria (25/Feb/2009)

UK. Doctors to find babies who had 'tainted jab' - The Independent

Doctors to find babies who had 'tainted jab'

By Steve Connor, Science Editor
Friday, 27 February 2009

Doctors have been asked to trace all babies in Britain who have been injected in the past month with the meningitis C vaccine which was recalled on Wednesday after it emerged that it may be contaminated with a microbe that can cause potentially fatal blood poisoning.


The Department of Health also announced it is also going to test unused batches of the vaccine sent from Italy and stored in GP surgeries in the UK to see whether any of them are contaminated with Staphylococcus aureus, the same type of microbe responsible for the hospital-acquired infection MRSA.

The health department said it does not yet know how many of the 17,000 doses of meningitis C vaccine sent to GPs on 22 January and 20 February ? but recalled on Wednesday night ? have been used as part of the national childhood vaccination programme. However, it is likely to be in the hundreds or possibly thousands.

"We can, and are going to, track the vaccine to individual GP surgeries. GPs can then contact the patients who have had the injection. Although, as we've said, this is as a precautionary measure and we are not aware of any problems in the UK," a spokeswoman for the health department said.

"We won't know how many doses have already been administered and how many are sitting in GPs' fridges until we have recalled them all. The health department has traced all the vaccine and knows where it is. It will be collected from GP surgeries," she added.

Novartis, the Swiss pharmaceuticals company, manufactured its Menjugate vaccine for meningitis C at its facility in Italy, and the product destined for Britain had passed all sterility tests required under European Union regulations.

However, Novartis subsequently detected Staphylococcus contamination in samples taken from two batches that had already been sent to Britain by road. The samples were being used in an experiment to test their vulnerability to pressure changes when shipped by air and they were found to be positive on arrival in the US, a Novartis spokeswoman said.


Novartis informed the British distributor of the problem late on Friday night of last week by email, and the company subsequently telephoned the Department of Health on Monday morning, a spokesman said. The health department said it checked with the company on Monday morning to make sure it had informed the medicines watchdog, the Medicines Healthcare Products Regulatory Agency (MHRA) but the agency said that it was only told about the problem on Tuesday.

The MHRA recalled the vaccine on Wednesday night several hours after the health department had been approached by The Independent with questions about the possible contamination of the baby vaccine.

Professor Kent Woods, chief executive of the MHRA, said there was currently no evidence that any children have been harmed by the suspect stocks of meningitis C vaccine and there have been no reports of any infections following vaccination.


"Parents should not be concerned over this recall, as there is currently no evidence to show UK children have been put at risk. Novartis are recalling these two batches as a precautionary measure," Professor Woods said.

More than 60,000 doses of vaccine formed the two batches sent from Italy. The Deparment of Health said that more than 21,000 of those had been shipped to GP surgeries but yesterday it revised that figure down to 17,000.

A spokeswoman for Novartis said the vaccine is transported in vials separated from a liquid solvent in which it is mixed on arrival. It was the liquid solvent ? aluminium hydroxide ? that was found to be contaminated.

"The solvent that was transported by road to the UK passed all routine checks but the solvent that was transported by road and air to the US did not," she said.
-
<cite cite="http://www.independent.co.uk/life-style/health-and-wellbeing/health-news/doctors-to-find-babies-who-had-tainted-jab-1633390.html">Doctors to find babies who had 'tainted jab' - Health News, Health & Wellbeing - The Independent</cite>
 
Back
Top Bottom